Cognition completes End-of-Phase 2 meeting with FDA for zervimesine

Cognition Therapeutics (CGTX) conducted an end-of-Phase 2 meeting with the U.S. Food and Drug Administration on July 9, 2025. The objective of this meeting was to review results from the Phase 2 study of zervimesine and to discuss plans for a Phase 3 program that would support a new drug application for zervimesine as a treatment for Alzheimer’s disease. Lisa Ricciardi, CEO stated, “We discussed the results from the Phase 2 ‘SHINE’ Study in Alzheimer’s disease and our proposed Phase 3 plan with the FDA and believe we have a path forward for the development of zervimesine in the treatment of Alzheimer’s disease. We look forward to reviewing the FDA’s formal minutes in August to confirm our path forward.”